Ultime notizie per Waters (NYSE:WAT) Azioni

Waters

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.

Waters Corp

Energous Corp

WATERMARK LODGING TRUST A by Watermark Lodging Trust Inc.

WATCHES OF SWITZERLAND G by Watches of Switzerland Group PLC

Watches of Switzerland Group PLC

WATER INTELLIGENCE PLC by Water Intelligence PLC

Water Intelligence PLC

WATER OASIS GROUP LTD by Water Oasis Group Ltd.

Water Oasis Group Ltd

WATER TECH INTL by Water Technologies International,Inc.

Water Technologies International Inc

WATER WAYS TECHS INC by WATER WAYS TECHNOLOGIES INC

Water Ways Technologies Inc

WATERPURE INTL INC by WaterPure International, Inc.

WaterPure International Inc

Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A Ordinary Shares)

Waterdrop Inc

Waterloo Brewing Ltd

Waterstone Financial, Inc. - Common Stock

Waterstone Financial Inc

Watsco Inc

Watts Co Ltd

Watts Water Technologies, Inc. Class A Common Stock

Watts Water Technologies Inc

12 analysts have shared their evaluations of Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Waters and provided 12-month price targets. The average target is $380.83, accompanied by a high estimate of $430.00 and a low estimate of $325.00. This current average reflects an increase of 10.53% from the previous average price target of $344.55. 
<img src="https://www.benzinga.com/files/images/story/2024/1734976853_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Waters among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$430.00</td>
<td>-</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$430.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$325.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$360.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$410.00</td>
<td>$363.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$360.00</td>
<td>$332.00</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$380.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$415.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$360.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$330.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$415.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$355.00</td>
<td>$335.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Waters. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Waters's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Waters's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waters analyst ratings.</a>
<h2>All You Need to Know About Waters</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
<h3>Financial Insights: Waters</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Waters showcased positive performance, achieving a revenue growth rate of 4.02% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 21.82%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Waters's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.71% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Waters's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.6% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 1.19, Waters faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About Waters Stock

Scotiabank analyst Sung Ji Nam initiates coverage on Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Sector Perform rating and announces Price Target of $430.

News

Price Target

Initiation

Scotiabank Initiates Coverage On Waters with Sector Perform Rating, Announces Price Target of $430

The companies plan to combine their complementary expertise on charge separation (Bio-Techne's MauriceFlex System) and liquid chromatography-mass spectrometry (BioAccord LC-MS System from Waters) to deliver innovative solutions that optimize workflows, improve precision, and accelerate development timelines.

Health Care

Contracts

General

TECH

Bio-Techne Announced Co-marketing And Co-Promotion Agreement With Waters Corporation Aimed At Expanding The Reach Of Advanced Biotherapeutic Characterization And Development Processes

B of A Securities analyst Derik De Bruin maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Neutral and raises the price target from $400 to $430.

B of A Securities Maintains Neutral on Waters, Raises Price Target to $430

Deutsche Bank analyst Justin Bowers maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Hold and raises the price target from $310 to $325.

Deutsche Bank Maintains Hold on Waters, Raises Price Target to $325

Bernstein analyst Eve Burstein maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Market Perform and raises the price target from $345 to $360.

Bernstein Maintains Market Perform on Waters, Raises Price Target to $360

TD Cowen analyst Dan Brennan maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Hold and raises the price target from $363 to $410.

TD Cowen Maintains Hold on Waters, Raises Price Target to $410

Stifel analyst Daniel Arias maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Hold and raises the price target from $332 to $360.

Stifel Maintains Hold on Waters, Raises Price Target to $360

JP Morgan analyst Rachel Vatnsdal maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Neutral and raises the price target from $340 to $380.

JP Morgan Maintains Neutral on Waters, Raises Price Target to $380

6 analysts have shared their evaluations of Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Waters, revealing an average target of $372.5, a high estimate of $415.00, and a low estimate of $330.00. Marking an increase of 9.56%, the current average surpasses the previous average price target of $340.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1730729020_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Waters is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$415.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$360.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$330.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$415.00</td>
<td>$355.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$355.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$360.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Waters. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Waters compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Waters's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Waters's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WAT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Waters analyst ratings.</a>
<h2>Delving into Waters's Background</h2>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
<h3>Waters: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Waters showcased positive performance, achieving a revenue growth rate of 4.02% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Waters's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.82% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Waters's ROE stands out, surpassing industry averages. With an impressive ROE of 10.71%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Waters's ROA excels beyond industry benchmarks, reaching 3.6%. This signifies efficient management of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.19, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 6 Ratings For Waters

Wells Fargo analyst Brandon Couillard maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Overweight and raises the price target from $380 to $415.

Wells Fargo Maintains Overweight on Waters, Raises Price Target to $415

Barclays analyst Luke Sergott maintains Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) with a Underweight and raises the price target from $330 to $360.

Barclays Maintains Underweight on Waters, Raises Price Target to $360

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares jumped 38.86% after the company reported third-quarter results and issued&nbsp;Q4&nbsp;revenue&nbsp;guidance&nbsp;above estimates, and many <a href="https://www.benzinga.com//node/41631795" target="_blank" rel="noreferrer noopener">analysts raised the price forecast</a>.</li>
<li>Paycom Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) stock escalated 27.95% after the company reported third-quarter results and <a href="https://www.benzinga.com/quote/payc/analyst-ratings" target="_blank" rel="noreferrer noopener">analysts boosted the price forecast</a>.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) gained 22.89% last week after the <a href="https://www.benzinga.com//node/41653083" target="_blank" rel="noreferrer noopener">company reported Q3 earnings</a> and sales that beat analyst estimates. Many analysts revised their <a href="https://www.benzinga.com/quote/mbly/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) gained 22.43% after reporting better-than-expected Q3 earnings and raising its FY24 sales outlook. Many <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings" target="_blank" rel="noreferrer noopener">analysts also raised their price forecasts for</a> the stock.</li>
<li>Garmin Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>)&nbsp;shares surged 22.11% after the company reported&nbsp;Q3 financial results <a href="https://www.benzinga.com//node/41625504" target="_blank" rel="noreferrer noopener">and raised its annual&nbsp;outlook</a>.</li>
<li>Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) shares increased 22.07% after the company reported better-than-expected&nbsp;third-quarter results and a year-over-year increase in daily <a href="https://www.benzinga.com//node/41654520" target="_blank" rel="noreferrer noopener">active users and hours engaged</a>. Many analysts upped the <a href="https://www.benzinga.com/quote/rblx/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) stock increased 20.39% after the company reported better-than-<a href="https://www.benzinga.com//node/41639676" target="_blank" rel="noreferrer noopener">expected&nbsp;financial results</a>. Several analysts boosted the <a href="https://www.benzinga.com/quote/twlo/analyst-ratings" target="_blank" rel="noreferrer noopener">stock&#8217;s price forecast</a>.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares rose 19.90% after the company reported quarterly results and several analysts revised the <a href="https://www.benzinga.com//node/41633681" target="_blank" rel="noreferrer noopener">stock&#8217;s price forecast</a>.</li>
<li>Waters Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) shares gained 19.31% last week. The company reported better-than-expected Q3 earnings and raised its annual outlook.</li>
<li>Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) climbed 18.87% last week on Q1 earnings and a strong Q2 outlook. The company&#8217;s board approved a new $1.5 billion share repurchase program, and many <a href="https://www.benzinga.com/quote/team/analyst-ratings" target="_blank" rel="noreferrer noopener">analysts boosted the stock&#8217;s price forecast</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41702898/super-micro-computer-li-auto-and-estee-lauder-are-among-top-10-large-cap-losers-last-week-oct-28-n">Super Micro Computer, Li Auto And Estee Lauder Are Among Top 10 Large Cap Losers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?</a></li>
</ul>
Image via Shutterstock

Large Cap

Movers

Trading Ideas

EXEL

GRMN

MBLY

PAYC

RBLX

RDDT

SNAP

TEAM

TWLO

Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?

Wall Street rebounded Friday following Thursday&#8217;s selloff, yet midday gains were still insufficient to prevent a second consecutive weekly decline for the S&amp;P 500, currently <a href="https://www.benzinga.com/markets">down 1% for the week. </a>
Concerns over tech earnings eased after Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) outperformed expectations, restoring some risk appetite and supporting the sector rebound.
Amazon shares surged over 6%, heading for their best session since February.
The Nasdaq 100, up by 1.1%, outperformed the S&amp;P 500, up 0.8%. 
In economic data, the U.S. economy added just 12,000 jobs in October, a steep drop from the 223,000 gain in September and well below the forecast of 113,000, as hurricanes and strikes led to hiring freezes nationwide. 
Despite the weak job figures, the unemployment rate held steady at 4.1%, indicating companies chose to retain workers rather than downsize.
The ISM Manufacturing PMI signaled contraction for the seventh consecutive month in October, with the index missing estimates.
Oil prices experienced a volatile session, initially spiking on reports of an imminent retaliatory attack by Iran on Israel before pulling back as those concerns faded. Gold edged down 0.1%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dipped 0.3%, slipping below the $70,000 mark.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,123.15</td>
<td>1.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,161.88</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,751.05</td>
<td>0.8%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,209.70</td>
<td>0.6%</td>
</tr>
</tbody>
</table>
</figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110124&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.9% to $573.75.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 1.1% to $422.09.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.2% to $489.80.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.8% to $219.26.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, rising 2%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.4%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), down 1.6%.</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), up over 6%.</li>
<li>Atlassian Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>), up 20%.</li>
<li>Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), down 0.7%.</li>
<li>Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), up 2.8%.</li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), up 13%.</li>
<li>Dominon Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>), down 0.2%.</li>
<li>Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), up 6%.</li>
<li>CBOE Global Markets Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#NYSE">CBOE</a>), down 2.9%.</li>
<li>Waters Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>), up 17%.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41690576/apple-q4-results-better-than-feared-analysts-highlight-iphone-16-demand-apple-intel">Apple Q4 Results &#8216;Better-Than-Feared&#8217;: Analysts Highlight iPhone 16 Demand, Apple Intelligence Opportunity After &#8216;Rock Solid Quarter&#8217;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Earnings

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

AAPL

AMZN

CBOE

CHTR

SPDR Dow Jones Industrial Average ETF Trust

INTC

Select Sector SPDR-Consumer Discretionary

Tech Stocks Surge But S&P 500 Faces Second Weekly Decline, Amazon Rallies, Bitcoin Drops Below $70,000: What's Driving Markets Friday?

U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Friday.
Shares of Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) rose sharply during Friday's session as the company posted stronger-than-expected results for the <a href="https://www.benzinga.com/quote/AMZN">third quarter on Thursday</a>.
Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data from Benzinga Pro. The company said it sees fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year.
Amazon.com shares jumped 7.1% to $199.63 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Proto Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) shares jumped 31.8% to $36.10 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) gained 30% to $22.72 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
<li>Globalstar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) jumped 25.3% to $1.3145 after the company amended its services agreement with Apple to launch an extended MSS network with new satellites and infrastructure.</li>
<li>ADMA Biologics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) gained 19.7% to $19.52.</li>
<li>Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) rose 17.3% to $378.98 after the company reported third-quarter earnings and sales that beat analyst estimates.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) gained 16.5% to $96.73 following third-quarter results.</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) climbed 15.8% to $218.37 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates.</li>
<li>Pediatrix Medical Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) rose 15.6% to $14.26 following better-than-expected quarterly earnings.</li>
<li>ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) gained 14.2% to $7.98. ASP Isotopes announced the pricing of public offering of common stock.</li>
<li>Select Medical Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) surged 13.2% to $36.32 following better-than-expected quarterly earnings.</li>
<li>Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) gained 12% to $366.93 after the company reported better-than-expected quarterly EPS and revenues.</li>
<li>Liberty Broadband Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>) gained 11.5% to $89.49.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) gained 9.9% to $55.56 after the company reported better-than-expected quarterly financial results and issued FY24 adjusted EPS guidance above estimates.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) rose 9.6% to $14.92.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) surged 8.2% to $133.01 after the company raised its FY2024 adjusted EPS guidance.</li>
<li>Chart Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NASDAQ">GTLS</a>) gained 8.1% to $130.46 following quarterly results.</li>
<li>Dorman Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DORM#NASDAQ">DORM</a>) gained 7.9% to $123.05 following upbeat earnings.</li>
<li>Magna International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGA#NYSE">MGA</a>) jumped 7.8% to $42.54 following third-quarter results.</li>
<li>Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) gained 7.1% to $116.21 after the company reported better-than-expected first-quarter EPS and revenues and raised its FY2025 adjusted EPS guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Intraday Update

Markets

ADMA

ASPI

DORM

GSAT

GTLS

HALO

LBRDA

PRLB

TILE

Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday

WIIM

Waters shares are trading higher after the company reported Q3 earnings and sales that beat analyst estimates.

The Company now expects full-year 2024 organic constant currency sales growth to be in the range of -2.0% to -0.5%. Currency translation is expected to decrease full-year sales growth by approximately 1.5%. M&amp;A contribution from the Wyatt transaction covering the first four-and-a-half months of the year has added 1.3% to full-year reported sales.&nbsp;

Guidance

Waters Corp Revises FY24 Reported Sales Growth To -0.8% To -0.2% (Prior View -2.2% To -0.7%), Adj EPS Forecast From  $11.55 - $11.65 To $11.67 - $11.87 (Est $11.60)

Waters Corp Expects Q4 Constant Currency Sales Growth To Be +5.0% To +7.0%, Adj EPS Of $3.90 - $4.10, Est $4.09

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) reported quarterly earnings of $2.93 per share which beat the analyst consensus estimate of $2.68 by 9.33 percent. The company reported quarterly sales of $740.30 million which beat the analyst consensus estimate of $713.02 million by 3.83 percent. This is a 4.02 percent increase over sales of $711.69 million the same period last year.

Earnings Beats

Waters Q3 2024 Adj EPS $2.93 Beats $2.68 Estimate, Sales $740.30M Beat $713.02M Estimate

Waters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) is preparing to release its quarterly earnings on Friday, 2024-11-01. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Waters to report an earnings per share (EPS) of $2.68.
Anticipation surrounds Waters's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.07 in the last quarter, leading to a 4.83% increase in the share price on the following day.
Here's a look at Waters's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.56</td>
<td>2.10</td>
<td>3.55</td>
<td>2.55</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.63</td>
<td>2.21</td>
<td>3.62</td>
<td>2.84</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730383280_0.png" alt="eps graph" />
<h3>Waters Share Price Analysis</h3>
Shares of Waters were trading at $326.59 as of October 30. Over the last 52-week period, shares are up 24.59%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on Waters</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Waters.
Waters has received a total of 4 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $365.0, the consensus suggests a potential 11.76% upside.
<h3>Peer Ratings Overview</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Avantor, Illumina and Revvity, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>The prevailing sentiment among analysts is an Outperform trajectory for Avantor, with an average 1-year price target of $28.67, implying a potential 91.22% downside.</li>
<li>As per analysts' assessments, Illumina is favoring an Neutral trajectory, with an average 1-year price target of $167.41, suggesting a potential 48.74% downside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Revvity, with an average 1-year price target of $135.0, indicating a potential 58.66% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary presents essential metrics for Avantor, Illumina and Revvity, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waters</td>
<td>Buy</td>
<td>-4.33%</td>
<td>$420.29M</td>
<td>10.70%</td>
</tr>
<tr>
<td>Avantor</td>
<td>Outperform</td>
<td>-2.36%</td>
<td>$581.50M</td>
<td>1.73%</td>
</tr>
<tr>
<td>Illumina</td>
<td>Neutral</td>
<td>-5.44%</td>
<td>$721M</td>
<td>-55.45%</td>
</tr>
<tr>
<td>Revvity</td>
<td>Outperform</td>
<td>-2.45%</td>
<td>$385.51M</td>
<td>0.70%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Waters ranks highest in Gross Profit and Return on Equity among its peers. However, it ranks lowest in Revenue Growth. Overall, Waters is positioned in the middle compared to its peers based on the provided metrics.
<h3>Get to Know Waters Better</h3>
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.
<h3>A Deep Dive into Waters's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Waters's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -4.33%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Waters's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.15% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Waters's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.7% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Waters's ROA stands out, surpassing industry averages. With an impressive ROA of 3.19%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Waters's debt-to-equity ratio stands notably higher than the industry average, reaching 1.48. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<a href="https://www.benzinga.com/quote/WAT/earnings">To track all earnings releases for Waters visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Waters's Earnings Forecast

Life sciences stocks viewed positively at TD Cowen despite post-election weakness

Jefferies analyst Tycho Peterson maintained a Buy rating on Waters (WAT – Research Report) today and set a price target of $415.00. The company's s...

Jefferies Keeps Their Buy Rating on Waters (WAT)

Tracking Al Gore's Generation Investment Management Portfolio - Q3 2024 Update

The London Company SMID Cap Q3 2024 Portfolio Commentary

Tracking Terry Smith's Fundsmith 13F Portfolio - Q3 2024 Update

Analyst Puneet Souda from Leerink Partners maintained a Buy rating on Waters (WAT – Research Report) and increased the price target to $410.00 from...

Strategic Growth and Risk Mitigation Position Waters for Robust Expansion

BofA raised the firm's price target on Waters (WAT) to $430 from $400 and keeps a Neutral rating on the shares. The Life Sciences Tools sector unde...

Waters price target raised to $430 from $400 at BofA

As previously reported, Scotiabank initiated coverage of Thermo Fisher Scientific (TMO), Danaher (DHR), Waters Corporation (WAT), all with Sector P...

Scotiabank starts coverage on large cap life science tools trio

Scotiabank initiated coverage of Waters (WAT) with a Sector Perform rating and $430 price target as the firm began coverage of three life science t...

Waters initiated with a Sector Perform at Scotiabank

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Pony AI, Thermo Fisher initiated: Wall Street's top analyst calls

ACRS

ADPT

AMAT

APLT

AVTR

BRKR

CBRE

CLVT

ENGN

ENTG

EXAS

EXPO

FTNT

GCMG

GOOG

GOOGL

HSIC

HTHT

IDXX

IIPR

ILMN

LRLCF

MDXH

MELI

MEOBF

MESO

MSFT

MYGN

NONOF

NTNX

NTRA

OTIS

PACB

PONY

RELY

RVTY

SCHW

SMTI

SOPH

TOST

TRMB

TSMWF

TYGO

VEEV

VRSK

VRSN

WDAY

ZBRA

Press Releases

Waters Corporation Schedules Third Quarter 2024 Earnings Conference Call

Commodities

New Waters Discovery Core Rheometer Brings the Power of Rheology to Routine Quality Control Testing

Waters New Bioseparations Tools Accelerate and Improve Development of RNA-based Vaccines and Therapies Using LC-MS Analysis

Waters Corporation (NYSE: WAT) Reports Third Quarter 2024 Financial Results

Waters New Software Delivers Lab-Centric Business Intelligence and Enables Confident Audit-Readiness

Waters Corporation Opens State-of-the-Art Precision Manufacturing Facility in Longbridge, UK

Waters Corporation to Present at the Evercore 2024 HealthCONx Conference

Waters Highlights Continued Progress Towards Sustainability Commitments

Waters Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Waters Corporation Named to Dow Jones Sustainability Index for the Fourth Consecutive Year

Comments

Waters

Notizie

Ultime notizie per Waters (NYSE:WAT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO